Prognostic value of CD57(+) T lymphocytes in the peripheral blood of patients with advanced gastric cancer
- PMID: 19093181
- DOI: 10.1007/s10147-008-0789-8
Prognostic value of CD57(+) T lymphocytes in the peripheral blood of patients with advanced gastric cancer
Abstract
Background: Natural killer (NK)-like T cells comprising CD56(+) T cells and CD57(+) T cells belong to a subset of CD1d-independent NKT cells playing an important role in regulating immune responses. Although NK-like T cells are reported to increase in patients with advanced gastric carcinomas, it remains unknown how NK-like T cells are involved in disease progression in gastric cancer patients.
Methods: The proportions of Th1 cells (interferon [IFN]-gamma-producing CD4(+) T cells), Th2 cells (IL-4-producing CD4(+) T cells), and NK-like T cells (CD56(+) T cells and CD57(+) T cells) in the peripheral blood of 48 gastric cancer patients and 20 healthy controls were measured by two-color flow cytometry analysis and by intracellular cytokine analysis to investigate an association of these immune cells with the survival rate of gastric cancer patients.
Results: Univariate analysis showed that Th1 cells and CD57(+) T cells, as well as some clinicopathological factors, significantly influenced the survival rate. CD57-high (> or ==18%) patients survived for a significantly shorter period after surgery compared to CD57-low patients (P = 0.046; Kaplan-Meier, log-rank test) in the stage III-IV patients, but not in the stage I-II patients. Further, multivariate analysis showed that lymphatic invasion was a statistically significant independent risk factor in all the gastric cancer patients, but the proportion of CD57(+) T cells as well as depth of tumor were statistically significant independent risk factors in patients with advanced carcinomas (stage III-IV).
Conclusion: An increased proportion (> or ==18%) of CD57(+) T cells in the peripheral blood of patients with advanced gastric carcinomas could indicate a poor prognosis.
Similar articles
-
PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients.Int J Clin Oncol. 2010 Apr;15(2):145-52. doi: 10.1007/s10147-010-0033-1. Epub 2010 Mar 13. Int J Clin Oncol. 2010. PMID: 20229169 Clinical Trial.
-
The increase of CD57+ T cells in the peripheral blood and their impaired immune functions in patients with advanced gastric cancer.Oncol Rep. 2003 Sep-Oct;10(5):1443-8. Oncol Rep. 2003. PMID: 12883721
-
Evaluations of interferon-γ/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients.J Surg Oncol. 2010 Dec 1;102(7):742-7. doi: 10.1002/jso.21725. J Surg Oncol. 2010. PMID: 20872813
-
Analysis of Th1 and Th2 cytokines expressing CD4+ and CD8+ T cells in rheumatoid arthritis by flow cytometry.J Rheumatol. 2000 May;27(5):1128-35. J Rheumatol. 2000. PMID: 10813277
-
[Pre- and post-chemotherapy expressions of Th1 and Th2 type cytokines and their clinical significance in gastric cancer patients].Zhonghua Zhong Liu Za Zhi. 2008 Nov;30(11):844-7. Zhonghua Zhong Liu Za Zhi. 2008. PMID: 19173830 Chinese.
Cited by
-
MED15, transforming growth factor beta 1 (TGF-β1), FcγRIII (CD16), and HNK-1 (CD57) are prognostic biomarkers of oral squamous cell carcinoma.Sci Rep. 2020 May 21;10(1):8475. doi: 10.1038/s41598-020-65145-3. Sci Rep. 2020. PMID: 32439976 Free PMC article.
-
PSK may suppress CD57(+) T cells to improve survival of advanced gastric cancer patients.Int J Clin Oncol. 2010 Apr;15(2):145-52. doi: 10.1007/s10147-010-0033-1. Epub 2010 Mar 13. Int J Clin Oncol. 2010. PMID: 20229169 Clinical Trial.
-
CD8+ Immunosenescence Predicts Post-Transplant Cutaneous Squamous Cell Carcinoma in High-Risk Patients.J Am Soc Nephrol. 2016 May;27(5):1505-15. doi: 10.1681/ASN.2015030250. Epub 2015 Nov 12. J Am Soc Nephrol. 2016. PMID: 26563386 Free PMC article.
-
CD8+CD57+ T cells exhibit distinct features in human non-small cell lung cancer.J Immunother Cancer. 2020 Jun;8(1):e000639. doi: 10.1136/jitc-2020-000639. J Immunother Cancer. 2020. PMID: 32606053 Free PMC article.
-
Clinical and Histopathological Factors Associated with the Tumoral Expression of TGF-β1, MED15, CD16, and CD57 in Oral Squamous Cell Carcinoma.Adv Prev Med. 2022 Oct 27;2022:3145117. doi: 10.1155/2022/3145117. eCollection 2022. Adv Prev Med. 2022. PMID: 36340330 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials